Literature DB >> 7492098

Cross-resistance to polyene and azole drugs in Cryptococcus neoformans.

T Joseph-Horne1, D Hollomon, R S Loeffler, S L Kelly.   

Abstract

Fluconazole was observed to inhibit sterol 14 alpha-demethylase in the human pathogen Cryptococcus neoformans, and accumulation of a ketosteroid product was associated with growth arrest. A novel mechanism(s) of azole and amphotericin B cross-resistance was identified, unrelated to changes in sterol biosynthesis, as previously identified in Saccharomyces cerevisiae. Reduced cellular content of drug could account for the resistance phenotype, indicating the possible involvement of a mechanism similar to multidrug resistance observed in higher eukaryotes.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7492098      PMCID： PMC162775          DOI： 10.1128/AAC.39.7.1526

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals.

Authors:  P F Watson; M E Rose; S W Ellis; H England; S L Kelly
Journal:  Biochem Biophys Res Commun       Date:  1989-11-15       Impact factor: 3.575

2.  Fluconazole treatment of persistent Cryptococcus neoformans prostatic infection in AIDS.

Authors:  S A Bozzette; R A Larsen; J Chiu; M A Leal; J G Tilles; D D Richman; J M Leedom; J A McCutchan
Journal:  Ann Intern Med       Date:  1991-08-15       Impact factor: 25.391

3.  Isolation and analysis of ketoconazole resistant mutants of Saccharomyces cerevisiae.

Authors:  P F Watson; M E Rose; S L Kelly
Journal:  J Med Vet Mycol       Date:  1988-06

4.  Cancer chemotherapy. Progress in understanding multidrug resistance.

Authors:  G R Stark
Journal:  Nature       Date:  1986 Dec 4-10       Impact factor: 49.962

5.  Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient.

Authors:  S L Kelly; D C Lamb; M Taylor; A J Corran; B C Baldwin; W G Powderly
Journal:  FEMS Microbiol Lett       Date:  1994-09-15       Impact factor: 2.742

6.  Stereoselective interaction of an azole antifungal agent with its target, lanosterol 14 alpha-demethylase (cytochrome P-45014DM): a model study with stereoisomers of triadimenol and purified cytochrome P-45014DM from yeast.

Authors:  Y Yoshida; Y Aoyama
Journal:  Chirality       Date:  1990       Impact factor: 2.437

7.  Multiple functions for sterols in Saccharomyces cerevisiae.

Authors:  R J Rodriguez; C Low; C D Bottema; L W Parks
Journal:  Biochim Biophys Acta       Date:  1985-12-04

8.  Amphotericin B-induced oxidative damage and killing of Candida albicans.

Authors:  M L Sokol-Anderson; J Brajtburg; G Medoff
Journal:  J Infect Dis       Date:  1986-07       Impact factor: 5.226

9.  Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment.

Authors:  A Zuger; E Louie; R S Holzman; M S Simberkoff; J J Rahal
Journal:  Ann Intern Med       Date:  1986-02       Impact factor: 25.391

10.  Nystatin-resistant mutants of yeast: alterations in sterol content.

Authors:  R A Woods
Journal:  J Bacteriol       Date:  1971-10       Impact factor: 3.490
View more
  22 in total

Review 1.  Mechanisms of fungal resistance: an overview.

Authors:  Maher M Balkis; Steven D Leidich; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

Review 3.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

4.  Interactions of posaconazole and flucytosine against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; L K Najvar; R Bocanegra; F Caselli; S Di Cesare; D Giannini; L F Di Francesco; A Giacometti; F Carle; G Scalise; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

5.  Accumulation of 3-ketosteroids induced by itraconazole in azole-resistant clinical Candida albicans isolates.

Authors:  P Marichal; J Gorrens; L Laurijssens; K Vermuyten; C Van Hove; L Le Jeune; P Verhasselt; D Sanglard; M Borgers; F C Ramaekers; F Odds; H Vanden Bossche
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 6.  Regulatory circuitry governing fungal development, drug resistance, and disease.

Authors:  Rebecca S Shapiro; Nicole Robbins; Leah E Cowen
Journal:  Microbiol Mol Biol Rev       Date:  2011-06       Impact factor: 11.056

7.  Investigation of the Sterol Composition and Azole Resistance in Field Isolates of Septoria tritici.

Authors:  T Joseph-Horne; D Hollomon; N Manning; S L Kelly
Journal:  Appl Environ Microbiol       Date:  1996-01       Impact factor: 4.792

8.  A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function.

Authors:  J R Thompson; C M Douglas; W Li; C K Jue; B Pramanik; X Yuan; T H Rude; D L Toffaletti; J R Perfect; M Kurtz
Journal:  J Bacteriol       Date:  1999-01       Impact factor: 3.490

Review 9.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors:  B D Alexander; J R Perfect
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

10.  Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents.

Authors:  Dominique Sanglard; Françoise Ischer; Tania Parkinson; Derek Falconer; Jacques Bille
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.